Keyphrases
Disease Activity
100%
Multiple Sclerosis
100%
Recombinant
100%
Type I Interferon
100%
Endogenous Types
83%
Interferon-α (IFN-α)
66%
Multiple Sclerosis Treatment
50%
Magnetic Resonance Imaging
50%
T Cells
50%
CD4+
50%
CD26
50%
CD49d
50%
Treatment Effect
33%
HLA-DR
33%
CD4+ T Cells
33%
Interferon Therapy
33%
CD71
33%
VLA-4
33%
Flow Cytometry
16%
Beneficial Effects
16%
Monocytes
16%
Response to Therapy
16%
Disease Control
16%
Dendritic Cells
16%
Integrin
16%
Decreased Expression
16%
Helper Cells
16%
Lack of Response
16%
Clinical Disease Activity
16%
Cause-effect
16%
Treatment Type
16%
Interferon Treatment
16%
Low Disease Activity
16%
Activated T Cells
16%
Interferon-I
16%
CD4+ T Cell Subsets
16%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Activity
100%
Multiple Sclerosis
100%
Interferon
100%
Recombinant Interferon
100%
Interferon Type I
85%
Very Late Activation Antigen 4
28%
Flow Cytometry
14%
Integrin
14%
Immunology and Microbiology
Multiple Sclerosis
100%
interferon
100%
Recombinant Interferon
100%
T Cell
30%
Magnetic Resonance Imaging
23%
CD4
23%
T-Helper Cell
23%
CD49d
23%
HLA-DR
15%
VLA-4
15%
Monocyte
7%
T Cell Subset
7%
T Helper Cell
7%
Dendritic Cell
7%
Integrin
7%
Treatment of Multiple Sclerosis
7%
Neuroscience
Multiple Sclerosis
100%
Interferon
100%
Recombinant Interferon
100%
T Cell
53%
CD4
46%
Magnetic Resonance Imaging
23%
VLA-4
15%
HLA-DR
15%
Flow Cytometry
7%
Treatment of Multiple Sclerosis
7%
Integrin
7%